Midterm Results of Intravascular Lithotripsy for Severely Calcified Common Femoral Artery Occlusive Disease: A

Elda Chiara Colacchio1, Matteo Salcuni2, Angelo Gasparre3

  • 1Vascular and Endovascular Surgery Section, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.

Insights

Intravascular lithotripsy (IVL) offers a safe and effective endovascular option for treating severe common femoral artery (CFA) calcifications. This technique, combined with drug-coated balloon angioplasty, shows promising results for peripheral arterial disease (PAD).

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Endovascular Therapy

Background:

  • Traditional open surgery for common femoral artery (CFA) occlusive disease poses risks for frail patients.
  • Endovascular revascularization techniques are increasingly sought for peripheral arterial disease (PAD).
  • Intravascular lithotripsy (IVL) has demonstrated potential in treating lower limb arterial disease.

Purpose of the Study:

  • To evaluate the safety and efficacy of intravascular lithotripsy (IVL) for severely calcified common femoral artery (CFA) disease.
  • To report the experience with IVL as an endovascular treatment for complex PAD in the CFA.

Main Methods:

  • Prospective enrollment of 10 consecutive patients (12 limbs) with severe CFA PAD and calcification.
  • Treatment involved intravascular lithotripsy (IVL) followed by drug-coated balloon (DCB) angioplasty.
  • Primary outcomes included technical success, procedural success, clinical success, and target lesion revascularization (TLR).

Main Results:

  • 100% technical and procedural success was achieved with IVL and DCB angioplasty.
  • A median stenosis reduction of 55.5% was observed, with a significant improvement in Rutherford class.
  • Low rates of target lesion revascularization (8.3%) and no access site or distal embolization complications were reported.

Conclusions:

  • Intravascular lithotripsy (IVL) combined with drug-coated balloon (DCB) angioplasty appears safe and effective for selected cases of severe CFA calcified disease.
  • Further long-term follow-up and larger patient cohorts are necessary to validate these promising findings.
Abstract

Related Concept Videos

Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
25
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
23
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29